Better PAD care begins with seeing the disease differently. Honored to speak at #ESVS2026 to share our BTK imaging, redefining “no option CLTI”. Grateful to a forward-looking society helping move new science toward clinical practice. This is an incredible meeting and society!

Thank you @SVM_tweets for inviting me to share our work on predicting progression from PAD to CLTI. I’ve loved the passionate multidisciplinary conversations at my first SVM meeting and enjoyed it so much that I applied to join the Society! #VSS2026

First time at @SVM_tweets #VSS2026 in Atlanta! Looking forward to sharing our work on advanced PAD imaging and to finally put faces to the names of the many leaders in this society who have shaped how I think about vascular disease! @HMethodistCV

Happy Birthday @AlanLumsdenMD ! Age hasn't slowed him down a bit - still asking the hard questions, trying new things and keeping the rest of us on our toes to keep pushing #VascularSurgery forward!

Human cadaveric vessels purchased for device testing often don’t contain the lesions you need. Check out our paper from the @HMethodistCV PVD device core on how we’re tackling this problem to create realistic CTO models for testing the next generation of endovascular devices.

The clock doesn’t define the clot. Thrombi evolve heterogeneously, making symptom duration an imperfect guide for thrombectomy or lysis. MRI-based clot characterization brings precision medicine to DVT. Congrats to @VenousForum prize winner Dr. Pomozi! #EVF2026 @AlanLumsdenMD

OCT shows ~11% vessel coverage after DCB. And yet, we think we’ve delivered therapy. Maybe it’s not the device. Maybe it’s the patient/lesion. Better imaging is necessary! #CX2026 @AlanLumsdenMD @VascularABC @DeBakeyCVedu